Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01425879 · ClinicalTrials.gov registry record · Phase 2
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01425879: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01425879 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01425879, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase II trial is studying how well MD2206 works in treating patients with advanced refractory biliary cancer that cannot be removed by surgery.
Interventions
- OTHER Diagnostic Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- DRUG Akt Inhibitor MK2206
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01425879
The ClinicalTrials.gov registry entry for NCT01425879 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Diagnostic Laboratory Biomarker Analysis is the first listed.
NCT01425879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01425879 about?
NCT01425879 is a clinical study titled "MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery". This phase II trial is studying how well MD2206 works in treating patients with advanced refractory biliary cancer that cannot be removed by surgery.
What is the current status of trial NCT01425879?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2011-04. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01425879?
The interventions under investigation include: Diagnostic Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Akt Inhibitor MK2206 (DRUG).
Who is sponsoring clinical trial NCT01425879?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.